These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19253368)

  • 1. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation.
    van den Broek GB; Wildeman M; Rasch CR; Armstrong N; Schuuring E; Begg AC; Looijenga LH; Scheper R; van der Wal JE; Menkema L; van Diest PJ; Balm AJ; van Velthuysen ML; van den Brekel MW
    Int J Cancer; 2009 Jun; 124(11):2643-50. PubMed ID: 19253368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy.
    Gasparini G; Bevilacqua P; Bonoldi E; Testolin A; Galassi A; Verderio P; Boracchi P; Guglielmi RB; Pezzella F
    Clin Cancer Res; 1995 Nov; 1(11):1375-83. PubMed ID: 9815934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy.
    Homma A; Furuta Y; Oridate N; Nakano Y; Kohashi G; Yagi K; Nagahashi T; Yagi K; Nagahashi T; Fukuda S; Inoue K; Inuyama Y
    Clin Cancer Res; 1999 Apr; 5(4):801-6. PubMed ID: 10213215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
    Bache M; Reddemann R; Said HM; Holzhausen HJ; Taubert H; Becker A; Kuhnt T; Hänsgen G; Dunst J; Vordermark D
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1481-7. PubMed ID: 17056190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.
    Hoebers FJ; Pameijer FA; de Bois J; Heemsbergen W; Balm AJ; Schornagel JH; Rasch CR
    Head Neck; 2008 Sep; 30(9):1216-23. PubMed ID: 18642295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas.
    Moreno-Galindo C; Hermsen M; García-Pedrero JM; Fresno MF; Suárez C; Rodrigo JP
    Oral Oncol; 2014 Feb; 50(2):128-34. PubMed ID: 24239278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer.
    Pavón MA; Parreño M; León X; Sancho FJ; Céspedes MV; Casanova I; Lopez-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
    Int J Cancer; 2008 Sep; 123(5):1068-79. PubMed ID: 18546291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma.
    Michaud WA; Nichols AC; Mroz EA; Faquin WC; Clark JR; Begum S; Westra WH; Wada H; Busse PM; Ellisen LW; Rocco JW
    Clin Cancer Res; 2009 Mar; 15(5):1645-54. PubMed ID: 19240170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma.
    Chen YJ; Rau KM; Chien CY; Fang FM; Huang TL; Chiu TJ
    Asian Pac J Cancer Prev; 2011; 12(3):649-55. PubMed ID: 21627359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of multiple biological markers in radiotherapy-treated head and neck cancer.
    Silva P; Slevin NJ; Sloan P; Valentine H; Ryder D; Price P; West CM; Homer JJ
    J Laryngol Otol; 2010 Jun; 124(6):650-8. PubMed ID: 20388242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
    Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
    Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
    Jonathan RA; Wijffels KI; Peeters W; de Wilde PC; Marres HA; Merkx MA; Oosterwijk E; van der Kogel AJ; Kaanders JH
    Radiother Oncol; 2006 Jun; 79(3):288-97. PubMed ID: 16730088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
    Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma.
    van den Broek GB; Rasch CR; Pameijer FA; Peter E; van den Brekel MW; Tan IB; Schornagel JH; de Bois JA; Zijp LJ; Balm AJ
    Cancer; 2004 Oct; 101(8):1809-17. PubMed ID: 15386309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of cyclin D1 and p16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy.
    Higuchi E; Oridate N; Homma A; Suzuki F; Atago Y; Nagahashi T; Furuta Y; Fukuda S
    Head Neck; 2007 Oct; 29(10):940-7. PubMed ID: 17563903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53.
    Yip HT; Chopra R; Chakrabarti R; Veena MS; Ramamurthy B; Srivatsan ES; Wang MB
    Arch Otolaryngol Head Neck Surg; 2006 Mar; 132(3):317-26. PubMed ID: 16549753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response?
    Wildeman MA; Gibcus JH; Hauptmann M; Begg AC; van Velthuysen ML; Hoebers FJ; Mastik MF; Schuuring E; van der Wal JE; van den Brekel MW
    Laryngoscope; 2009 Feb; 119(2):316-22. PubMed ID: 19160427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of basaloid squamous cell carcinoma in head and neck cancer.
    Linton OR; Moore MG; Brigance JS; Gordon CA; Summerlin DJ; McDonald MW
    JAMA Otolaryngol Head Neck Surg; 2013 Dec; 139(12):1306-11. PubMed ID: 24158536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
    Ciaparrone M; Caspiani O; Bicciolo G; Signorelli D; Simonelli I; de Campora L; Mazzarella G; Mecozzi A; Pianelli C; Camaioni A; Catalano P; Pasqualetti P; Fabiano A; Radici M; Marmiroli L; Corsi DC
    Oncology; 2015; 89(4):227-34. PubMed ID: 26066774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review.
    Swartz JE; Pothen AJ; Stegeman I; Willems SM; Grolman W
    Cancer Med; 2015 Jul; 4(7):1101-16. PubMed ID: 25919147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.